Home
    Disclaimer

    Atomoxetine

    Aliases: Strattera

    Summary Erowid TripSit

    Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) approved as a less stimulating treatment for ADHD in 2002 (U.S.). The precise mechanism by which it produces its therapeutic effects is unknown, but is thought to be related to its SNRI action.

    Dose Information TripSit

    ROA Light Common Strong Heavy
    Oral 10-18mg 18-40mg 40-80mg 80mg+
    Light Common Strong Heavy

    Onset, Duration & After-effects TripSit

    ROA Onset Peak After Effects Total
    Oral 15-45 min 8-12 hrs 2-24 hrs 8.2-12.8 hrs

    Effect Profile

    35 reports

    Scores (1–10) curated from multiple sources:

    • Effect keyword matching from PsychonautWiki catalog
    • Validated against 35 Erowid trip reports
    • Weighted by importance: core (×3), major (×2), minor (×1)

    Full methodology

    Stimulant 7.2
    Strong+ 7/10

    Strong stimulation and anxiety/jitters with moderate euphoria and focus

    Stimulation / Energy ×3
    10
    stimulation wakefulness alertness enhancement
    Euphoria / Mood Lift ×2
    7
    euphoria cognitive euphoria
    Focus / Productivity ×2
    7
    Anxiety / Jitters ×1
    10
    anxiety restlessness increased heart rate vasoconstriction

    Tolerance

    Build-up develops over days to weeks of regular use
    Reset 3–7 days for acute tolerance; longer for full reset

    Tolerance Decay

    Full tolerance 1d Half tolerance 10d Baseline ~18d

    Effects Erowid

    Aggregated from 35 Erowid experience reports

    Positive Effects 8

    Focus Enhancement 51.4% 70%
    Stimulation 40.0% 70%
    Euphoria 20.0% 70%
    Empathy 17.1% 70%
    Body High 14.3% 70%
    Tactile Enhancement 11.4% 70%
    Color Enhancement 8.6% 70%
    Music Enhancement 8.6% 70%

    Adverse Effects 6

    Anxiety 45.7% 70%
    Nausea 28.6% 70%
    Headache 20.0% 70%
    Sweating 11.4% 70%
    Increased Heart Rate 8.6% 70%
    Jaw Clenching 8.6% 70%

    Pill Identifiers

    Helpful Links